Phase 3 Clinical Trials With Primary Completion Dates in April 2025
This is a list of Phase 3 trials with primary completion dates in April 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AKESF | Akeso, Inc. | 2025-04-01 | Phase 3 | NCT04982237 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer |
| ANGO | AngioDynamics, Inc. | 2025-04-01 | Phase 3 | NCT03899636 | A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer |
| BHVN | Biohaven Ltd. | 2025-04-01 | Phase 3 | NCT04693351 | Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder |
| CASBF | CanSino Biologics Inc. | 2025-04-01 | Phase 3 | NCT05951725 | A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) |
| CSPCY | CSPC Pharmaceutical Group Limited | 2025-04-01 | Phase 3 | NCT06383702 | A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy |
| IONS | Ionis Pharmaceuticals, Inc. | 2025-04-01 | Phase 3 | NCT05079919 | A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia |
| LVZPF | Livzon Pharmaceutical Group Inc. | 2025-04-01 | Phase 3 | NCT06110676 | A Study to Evaluate the Efficacy and Safety of LZM012 |
| XENE | Xenon Pharmaceuticals Inc. | 2025-04-01 | Phase 3 | NCT05614063 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures |
| ZLDPF | Zealand Pharma A/S | 2025-04-01 | Phase 3 | NCT04881825 | Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial |